Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
RBS-001 vs Eylea for Age-Related Macular Degeneration
Recruiting2 awardsPhase 3
Willow Park, Texas
This trial aims to show that two different treatments, RBS-001 and Eylea, are equally effective and safe in treating a specific eye condition called Neovascular age-related macular degeneration
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service